The Ministry of Food and Drug Safety (MFDS) has virtually thrown out a re-evaluation card for choline alfoscerate formulations, which are the controversy of effectiveness in full swing. The MFDS instructed 130 pharmaceutical companies producing choline alfoscerate to submit safety and efficacy data by Nov 11th 2019.

The re-evaluation of Choline alfoscerate formulations is about nine years since the document reevaluation in 2010. The MFDA's initiation of re-evaluation is considered as a follow up on the National Assembly's investigation in relation to government.

However, the MFDA went through a safety and efficacy review procedure for the same formulations last year under the name of '